Literature DB >> 14768526

Diphenylcyclopropenone (diphencyprone, DPCP) in the treatment of chronic severe alopecia areata (AA).

I Galadari1, S Rubaie, J Alkaabi, H Galadari.   

Abstract

BACKGROUND: Diphenylcyclopropenone (DPCP) has been reported to be an effective topical immunotherapy of extensive alopecia areata (AA) with highly variable reported results.
OBJECTIVE: The purposes of this study were to assess the efficacy, side effects, and adverse prognostic factors in the treatment of alopecia areata with DPCP.
METHODS: 21 patients were included in the study with chronic and extensive AA. Patients were sensitized in the beginning with 2% DPCP, and the concentrations were increased gradually beginning with 0.000001% every one to two weeks for a period of 6 months.
RESULTS: 15 patients (71.4%) had a complete or partial recovery at the end of the treatment period. Most frequent side effects were erythema at the site of application, pigmentation, and lymph node enlargement. The most important adverse prognostic factors were duration of AA, history of atopy, and presence of nail changes.
CONCLUSION: Treatment of AA with topical DPCP is effective. Though the treatment may have some side effects, in most cases they are tolerable and respond well to treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14768526

Source DB:  PubMed          Journal:  Eur Ann Allergy Clin Immunol        ISSN: 1764-1489


  3 in total

Review 1.  Alopecia Areata: a Comprehensive Review of Pathogenesis and Management.

Authors:  Ralph M Trüeb; Maria Fernanda Reis Gavazzoni Dias
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

2.  The C3H/HeJ mouse and DEBR rat models for alopecia areata: review of preclinical drug screening approaches and results.

Authors:  Jing Sun; Kathleen A Silva; Kevin J McElwee; Lloyd E King; John P Sundberg
Journal:  Exp Dermatol       Date:  2008-10       Impact factor: 3.960

3.  The efficacy of topical diphencyprone in the treatment of alopecia areata.

Authors:  Akhyani Maryam; Seirafi Hassan; Farnaghi Farshad; Banan Parastoo; Lajevardi Vahide
Journal:  Indian J Dermatol       Date:  2009       Impact factor: 1.494

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.